Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul;14(7):2522-2531.
doi: 10.21037/jtd-22-145.

Differences in pulmonary nodular consolidation and pulmonary cavity among drug-sensitive, rifampicin-resistant and multi-drug resistant tuberculosis patients: a computerized tomography study with history length matched cases

Affiliations

Differences in pulmonary nodular consolidation and pulmonary cavity among drug-sensitive, rifampicin-resistant and multi-drug resistant tuberculosis patients: a computerized tomography study with history length matched cases

Qi-Sheng Song et al. J Thorac Dis. 2022 Jul.

Abstract

Background: There have been concerns that literature described radiological feature differences between drug-sensitive pulmonary tuberculosis (DS-PTB) and multidrug-resistant (MDR)-PTB were confounded by that MDR-PTB cases tend to have a longer history. Using history length matched DS-PTB and MDR-PTB cases from a well-defined urban region in Dalian, we retrospectively analysed the CT feature differences of these paired cases with a focus on pulmonary nodular (PN) consolidation and pulmonary cavity (PC).

Methods: There were 33 consecutive MDR-PTB cases [inclusive of rifampicin-resistant (RR) cases, 27 males and 6 females, mean age: 49.2 years], with 19 cases had a history of <1 month and 8 and 6 cases had a history of 1-6 and >6 months respectively. To pair the MDR-PTB cases with history length, matched 33 cases of DS-PTB patients (21 males and 12 females, mean age: 56.5 years) were included. All patients were new PTB without HIV infection. The first CT exams prior to treatment were analysed.

Results: Compared with DS cases, MDR cases had a much higher prevalence of PN (75.76% vs. 45.45%) and a higher number of PN per positive case for PN (6.2 vs.1.53). For the cases >1 month history, MDR-PTB had a higher number of PC per positive case than that of DS-PTB cases (7.18 vs. 2.36). To differentiate DS-PTB from MDR-PTB, receiver operating characteristic (ROC) analysis showed a cutoff PN number of ≥3 had 48.5% sensitivity and 93.9% specificity, and a cutoff PC number of ≥4 had 39.4% sensitivity and 84.9% specificity. The lung field distribution of all lesions tended to be wider for MDR-PTB cases. MDR-PTB cases appeared to be associated with a faster progression in the absence of treatment.

Conclusions: MDR-TB is likely intrinsically more invasive than DS-TB. Multiple PN and Multiple PC are promising signs for the suspicion of MDR-PTB on chest imaging.

Keywords: Differential diagnosis; computed tomography; multidrug-resistant (MDR); pulmonary; tuberculosis (TB).

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-145/coif). YXJW is the founder of Yingran Medicals Co., Ltd., which develops medical image-based diagnostics software. YXJW serves as an unpaid editorial board member of Journal of Thoracic Disease from April 2022 to March 2024. The other authors have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Illustration of PN and PC. (A,B) Arrow indicates a PN; (C) arrow indicates a cavity with a well-defined wall; (D) arrow indicates a cavity and dotted arrow indicates a PN. *, an aggregation of many small nodules (<6 mm) not counted as PN. (E) Multiple worm-eroding like cavities counted as one cavity, the individual small cavities’ number was not counted in this study. (F) Arrow indicates a cavity and dotted arrow indicates a PN. *, an aggregation of two small nodules (<6 mm) not counted as PN. (G) Arrow indicates a cavity. PN, pulmonary nodular consolidation; PC, pulmonary cavity.
Figure 2
Figure 2
Prevalence (positive rate) and numbers of PN and PC for patients with a history of <1 month, 1–6 months, and >6 months. (A) Number of PN per case; (B) number of PC per case; (C) mean number of PN per case; (D) mean number of PC per case. MDR, multidrug-resistant; DS, drug-sensitive; PC, pulmonary cavity; PN, pulmonary nodular consolidation.
Figure 3
Figure 3
Difference of PN and PC numbers for DS and MDR patients. (A,B) Cases with the largest number of PN or PC are arranged first. (C) Distribution of DS cases (green dots) and MDR (red dots) in a 3-dimensional space with its axis being number of PN, number of PC, and the maximum diameter of PC for each case. A trend of differentiation for DS and MDR cases is noted, but there are also overlaps. MDR, multidrug-resistant; DS, drug-sensitive; PN, pulmonary nodular consolidation; PC, pulmonary cavity.

Similar articles

Cited by

References

    1. World Health Organization. Global Tuberculosis Report 2019. Available online: https://www.who.int/publications/i/item/9789241565714
    1. Raviglione MC, Smith IM. XDR tuberculosis--implications for global public health. N Engl J Med 2007;356:656-9. 10.1056/NEJMp068273 - DOI - PubMed
    1. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006;368:2142-54. 10.1016/S0140-6736(06)69863-2 - DOI - PubMed
    1. Parida SK, Axelsson-Robertson R, Rao MV, et al. Totally drug-resistant tuberculosis and adjunct therapies. J Intern Med 2015;277:388-405. 10.1111/joim.12264 - DOI - PubMed
    1. Knight GM, McQuaid CF, Dodd PJ, et al. Global burden of latent multidrug-resistant tuberculosis: trends and estimates based on mathematical modelling. Lancet Infect Dis 2019;19:903-12. 10.1016/S1473-3099(19)30307-X - DOI - PMC - PubMed